Home > Research Programs > Growth Factors Group
Growth Factors Group
Strategic Goals
- Cell surface remodeling during tumor progression
- HER2 signaling in breast cancer progression and treatment
- Targeting breast cancer initiating cells
Current objectives
- To identify novel factors and mechanisms involved in the progression of HER2-positive breast cancers.
Team
Post-doctoral Fellows
- Kim Pedersen PhD
- Josep Lluís Parra-Palau PhD
- Jordi Malapeira Argilaga PhD
- Beatriz Morancho Armisen PhD
Graduate Students
- Cristina Bernadó Morales
- Pier Davide Angellini
Technicians
- Antoni Luque Garcia
- Marta Escorihuela Baez
- Cristina Ferrer Ramón
Publications
- Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010 Jan; 29(3): 325-34
- Esselens C, Malapeira J, Colomé N, Casal C, Rodríguez-Manzaneque JC, Canals F, Arribas J. The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J. Biol. Chem. 2010 Jan; 285(4): 2463-73
- García-Castillo J, Pedersen K, Angelini PD, Bech-Serra JJ, Colomé N, Cunningham MP, Parra-Palau JL, Canals F, Baselga J, Arribas J. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. J. Biol. Chem. 2009 Sep; 284(37): 25302-13
- Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramón C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, Ramón y Cajal S, Baselga J, Arribas J. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 2009 Jun; 29(12): 3319-31
- Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramón y Cajal S, Arribas J, Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009 Feb; 28(6): 803-14
